Literature DB >> 27116331

Reported cardiac phenotypes in hereditary hemorrhagic telangiectasia emphasize burdens from arrhythmias, anemia and its treatments, but suggest reduced rates of myocardial infarction.

C L Shovlin1, I Awan2, Z Cahilog2, F N Abdulla2, A E Guttmacher3.   

Abstract

INTRODUCTION: Cardiac phenotypes should be pronounced in hereditary hemorrhagic telangiectasia (HHT) due to frequent systemic arteriovenous malformations (AVMs), iron deficiency anemia, hypoxemia, hyperdynamic circulations, venous thromboemboli, and paradoxical emboli through pulmonary AVMs. METHODS/
RESULTS: In an international survey, 1025 respondents (median age 55years) met HHT diagnostic criteria: 942 (91.9%) reported nosebleeds, 452 (44.1%) at least daily. AVMs were commonly reported in pulmonary (544, 53%), hepatic (194, 18.9%) and/or cerebral (92, 9.0%) circulations. 770/1025 (75%) had used iron tablets, 256 (25.0%) intravenous iron, and 374 (36.5%) received blood transfusions. Arrhythmias were reported by 113/1025 (11%, including 44 (4.3%) with atrial fibrillation), angina by 36 (3.5%), and cardiac failure by 26 (2.5%). In multivariate logistic regression, these phenotypes were associated with hepatic AVMs/pulmonary hypertension (relatively interchangeable variables), blood transfusions, and intravenous iron. Cardiac insufficiency/failure often provokes intensive anemia treatments, but associations with arrhythmias, particularly with a greater transfusion burden, were less easy to explain. Myocardial infarction (23/1025; 2.2%), and abnormal coronary angiogram (≤31/76, ≤54%) rates appeared low. Provocative preliminary data were obtained including HHT-affected respondents' parents and grandparents in whom HHT could be confidently assigned, or excluded based on autosomal dominant inheritance patterns: in crude and survival analyses, myocardial infarctions were reported less frequently for individuals with HHT, particularly for males (p=0.001).
CONCLUSION: Arrhythmias are the most common cardiac phenotype in HHT, and likely to be aggravated by iron deficiency anemia, its treatments, and/or high output states due to AVMs. Myocardial infarction rates may be reduced in this apparently high risk population.
Copyright © 2016 The Authors. Published by Elsevier Ireland Ltd.. All rights reserved.

Entities:  

Keywords:  Arteriovenous malformations; Blood transfusions; Intravenous iron; Paradoxical emboli; Pulmonary hypertension; Venous thromboemboli

Mesh:

Year:  2016        PMID: 27116331     DOI: 10.1016/j.ijcard.2016.04.006

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  7 in total

1.  Mutational and phenotypic characterization of hereditary hemorrhagic telangiectasia.

Authors:  Claire L Shovlin; Ilenia Simeoni; Kate Downes; Zoe C Frazer; Karyn Megy; Maria E Bernabeu-Herrero; Abigail Shurr; Jennifer Brimley; Dilipkumar Patel; Loren Kell; Jonathan Stephens; Isobel G Turbin; Micheala A Aldred; Christopher J Penkett; Willem H Ouwehand; Luca Jovine; Ernest Turro
Journal:  Blood       Date:  2020-10-22       Impact factor: 22.113

2.  Safety of direct oral anticoagulants in patients with hereditary hemorrhagic telangiectasia.

Authors:  C L Shovlin; C M Millar; F Droege; A Kjeldsen; G Manfredi; P Suppressa; S Ugolini; N Coote; A D Fialla; U Geisthoff; G M Lenato; H J Mager; F Pagella; M C Post; C Sabbà; U Sure; P M Torring; S Dupuis-Girod; E Buscarini
Journal:  Orphanet J Rare Dis       Date:  2019-08-28       Impact factor: 4.123

3.  Left atrial appendage occlusion in a patient with hereditary hemorrhagic telangiectasia and atrial fibrillation - a therapeutic option worth considering.

Authors:  Maksymilian Mielczarek; Rafał Gałąska; Piotr Drewla; Dorota Kulawiak-Gałąska; Dariusz Ciećwierz; Marcin Gruchała
Journal:  Arch Med Sci Atheroscler Dis       Date:  2017-06-30

Review 4.  Pulmonary Arterial Hypertension and Hereditary Haemorrhagic Telangiectasia.

Authors:  Veronique M M Vorselaars; Anna E Hosman; Cornelis J J Westermann; Repke J Snijder; Johannes J Mager; Marie-Jose Goumans; Marco C Post
Journal:  Int J Mol Sci       Date:  2018-10-17       Impact factor: 5.923

5.  Hereditary Hemorrhagic Telangiectasia (HHT) and Survival: The Importance of Systematic Screening and Treatment in HHT Centers of Excellence.

Authors:  Els M de Gussem; Steven Kroon; Anna E Hosman; Johannes C Kelder; Martijn C Post; Repke J Snijder; Johannes J Mager
Journal:  J Clin Med       Date:  2020-11-06       Impact factor: 4.241

6.  Myocardial Infarction in a Patient With Hereditary Hemorrhagic Telangiectasia: A Case Report and Review of Literature.

Authors:  Suman Rao; Alisha Khan; Dana Aiello
Journal:  Cureus       Date:  2021-05-24

7.  Left Atrial Appendage Occlusion: A Therapeutic Option in a Patient With Atrial Fibrillation and Hereditary Hemorrhagic Telangiectasia.

Authors:  Luciana Frade; Cláudio Gouveia; Renato Guerreiro; Susana Jesus; Candida Fonseca
Journal:  Cureus       Date:  2021-06-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.